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ELAVIA, SWATI T., Ph.D. Effects of Consumption of Fatty Fish Rich in 
Omega-3 Polyunsaturated Fatty Acids on Plasma Lipids and Prothrombin 
Time in Hyperlipidemic Subjects. (1989) 
Directed by Dr. Karen L. Graves. 90 pp. 
The effects of consumption of low levels of omega-3 polyun­
saturated fatty acids (n-3 PUFAs) on plasma lipids and prothrombin 
time were examined in hyperlipidemic men (n = 18) attending a 
cardiac rehabilitation program. Three dietary treatments were 
evaluated: the men's customary, the American Heart Association Phase 
I diet, and a food source of n-3 PUFAs fed at two levels. Eight 
ounces of salmon were fed either two times or four times per week 
providing approximately 4.5 gm or 9 gm n-3 PUFAs per week, respec­
tively. A Latin-square design which allowed adjustment for any 
carry-over effect of previous treatment into the succeeding period 
without separating the three test periods by a washout phase was 
employed. Each man consumed all three diets but in a different 
sequency; each dietary treatment lasted four weeks. The salmon was 
prepared, packed, and distributed to the men after completion of their 
exercise program at the center. They were instructed to substitute 
the fish for an entree at lunch or dinner. Adherence to diet instruc­
tion was ascertained from a food diary kept for four days during the 
last week of each treatment phase. Fasting blood samples were 
collected at baseline and at the end of each dietary treatment phase. 
Triglycerides, total- and low-density-lipoprotein cholesterol (LDL-
cholesterol) were decreased and prothrombin time was increased during 
the fish consuming dietary phases. The greatest decline was observed 
in the blood lipid measures when eight ounces of salmon were fed four 
times per week as compared to the customary diet. Moderate amounts of 
fish, eight ounces of salmon fed two times per week, were only 
observed to reduce triglycerides in these hyperlipidemic men. It 
would appear that an increase in consumption of fish, rich in n-3 
PUFA, would be beneficial in the management of hyperlipidemia. 
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CHAPTER I 
INTRODUCTION 
Epidemiological observations on Greenland Eskimos and subse­
quent clinical studies have demonstrated that the consumption of 
omega-3 polyunsaturated fatty acids (n-3 PUFAs), i.e., eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA) abundant in marine 
organisms, may reduce the risk of coronary heart disease (CHD). 
Omega-3 polyunsaturated fatty acids appear to have two important 
effects in the body which impact on the pathogenesis of heart disease. 
These fatty acids are hypolipidemic, and they alter platelet adhesive­
ness. 
The hypolipidemic effects of n-3 PUFAs appear to be complex, 
and consistent results have only been achieved in those studies which 
used high levels of either fatty fish or fish oil extract. At high 
dosage normolipidemic individuals generally show a reduction in total 
cholesterol which is accompanied by a decrease in low density lipo­
protein (LDL). The hypolipidemic effect of n-3 PUFAs on triglycerides 
(TGs) is much more impressive, and the effect is observed at lower 
levels of n-3 PUFA consumption than required to produce a hypo-
cholesterol emic effect. 
There have been few studies which have attempted to determine 
the impact of consumption of low levels of n-3 PUFAs. Fehily, Burr, 
Phillips, and Deadman (1983) reported that 5 oz of fatty fish which 
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provided 3 g n-3 PUFAs per week, consumed twice a week had a bene­
ficial effect on TGs but not on cholesterol levels. A retrospective 
study conducted by Kromhout, Basschieter, and Coulander (1985) which 
examined fish consumption in 1960 with CHD mortality data collected 
in the 1980s suggested that subjects who consumed approximately 30 g 
of fish per day were less likely to die from CHD. They found no 
relationship between fish consumption and total cholesterol levels. 
It has been hypothesized that if similar amount of fish (2-4 servings 
per week) were consumed by subjects with hyperlipidemia the overall 
effect would be more dramatic (Leaf & Weber, 1988). 
Estimates of fatty fish consumption indicate that the general 
U.S. population probably accrues little benefit from the ingestion 
of n-3 PUFAs. The mean daily capita intake of fish is currently about 
14 g per day (approximately 3 oz per week) which provides approxi­
mately 0.04-0.15 g of n-3 PUFAs per day (Herold & Kinsella, 1986). 
Estimates of n-3 PUFA content of fatty fish range from 0.3-1.1 g per 
100 g dependent on the fish selected. Good fish choices would include 
salmon, mackerel, herring, sardines and trout. Any increase in fatty 
fish consumption might prove beneficial in reducing the risk of CHD, 
particularly in those individuals with elevated serum lipids. At 
present there is little information on the role of n-3 PUFAs fed at 
realistic levels in the management of hyperlipidemias. 
The present study was designed to determine the effect of 
supplementing the customary diet with a food source of n-3 PUFAs 
(salmon) on plasma lipid levels and prothrombin time in hyperlipidemic 
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men. Two levels of salmon were fed—one providing approximately 9 g 
and the other 4.5 g n-3 PUFAs per week. 
The specific objectives of the study were as follows: 
1. To study lipid (TG, total- and LDL-cholesterol) lowering 
effects of consumption of fish rich in n-3 PUFA. 
2. To determine the effect of feeding realistic amounts of 
fish on high density lipoprotein (HDL)-cholesterol. 
3. To examine the increase in prothrombin time of hyper-
lipidemic subjects on a fish supplemented diet. 
4. To compare the two levels of fish consumption with 
customary diet (American Heart Association [AHA Phase I]) 
of hyperlipidemics for their desirable effects and their 
acceptability. 
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CHAPTER II 
REVIEW OF LITERATURE 
Accumulating evidence from epidemiologic studies and controlled 
feeding trials indicate that n-3 PUFAs in the diet might have pro­
tective effects against CHD (Leaf & Weber, 1988). Populations con­
suming diets abundant in seafoods rich in n-3 PUFAs have a lower than 
expected incidence of CHD (Dyerberg & Bang, 19G2). The feeding trials 
have focused on the actions of the n-3 PUFAs in the body that mioht 
diminish the risk of CHD; first, the hypolipidemic effect and second, 
alteration in platelet function. This review is organized as follows: 
I. Epidemiological Studies 
II. Composition of n-3 PUFAs 
III. Effects of n-3 PUFAs on Plasma Lipids 
IV. Effects of n-3 PUFAs on Platelet Function 
I. Epidemiological Studies 
Several epidemiological-based comparison studies between 
Eskimos of Greenland and those residing in Denmark were conducted in 
the 1970s to explore the factors which could possibly explain the 
differences in CHD incidence (Bang & Dyerberg, 1972; Bang & Dyerberg, 
1980; Band, Dyerberg, & Nielsen, 1971; Dyerberg, Bang, & Hjorne, 
1975). These studies demonstrated that the Greenland Eskimos had 
lower serum TGs, lower very low density lipoprotein (VLDL), lower 
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LDL and higher HDL levels as compared to their Danish controls. All 
of these parameters have been associated with a decreased risk of 
cardiac disease. 
The diets of the Green!anders and Danes also differed. The 
Greenland Eskimos consumed nearly 1 lb (454 g) of fish per day, while 
the Danish Eskimos consumed less than 20 g of fish per day. The 
total amount of fat consumed by both groups was similar, approximately 
40% of evergy from fat. However, the fat composition of the diets 
differed; the diet of Greenlanders was low in saturated fatty acids 
(SFAs) and rich in n-3 PUFAs, whereas the diet of the Danes was 
higher in SFA and the predominant PUFA was n-6 PUFA from vegetable 
sources. The lower incidence of CHD in the Greenland Eskimo popula­
tion may in part be attributed to their abundant consumption of sea­
foods rich in n-3 PUFAs and lower ingestion of n-6 PUFA and SFAs as 
compared to the Danish population. 
Studies in Japan also support the hypothesis that the intake of 
fatty acids from marine sources might lower the incidence of CHD 
(Hirai, Hamazaki, Terano, Nishikawa, Tamura, Kumagai, & Sijiki, 1980). 
In Japan the lowest mortality rate from CHD is on the island of 
Okinawa where fish consumption is twice the national average. Hirai 
et al. (1980) compared a fishing village with a farming village for 
fish consumption and relative mortality rate from CHD. The average 
fish consumption in the fishing village was 250 g per day as compared 
to 90 g per day in the farming village. The mortality rate from CHD 
was found to be lower in the fishing village. 
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A study carried out in the Netherlands suggested that even a 
small intake of fish over a long period might reduce the incidence of 
coronary disease (Kromhout et al., 1985). Kromhout et al. (1985) 
investigated the association between fish consumption of 852 middle-
aged men in Zutphen, Netherlands and mortality attributed to coronary 
disease during the ensuing 20 years. The results revealed that sub­
jects who consumed fish each day in lybO had lower death rates from 
coronary artery disease. Mortality was more than 50% lower among men 
who 20 years earlier had said they ate at least 30 g of fish per day 
compared to those who ate no fish. The diet history indicated that 
about two thirds of the fish eaten by these men was lean fish (cod 
and plaice) and one third consisted of fatty fish (herring and 
mackerel). Although no relation was found between fish consumption 
and serum total cholesterol levels, Kromhout et al. (1985) concluded 
that as little as two fish dishes per week might be beneficial in 
preventing CHD. 
II. Composition of n-3 PUFAs 
Human diets contain two series of PUFAs: the n-6 and n-3, 
derived from linoleic acid (18:2 n6) and alpha!inoleic acid (18:3, 
n3), respectively. Omega-3 PUFAs differ from n-6 PUFAs in the posi­
tion of the first unsaturation from the methyl (omega) end. The 
first unsaturation in case of n-3 PUFAs occurs three carbon atoms 
distant from the methyl end of the chain, whereas n-6 PUFAs have the 
first unsaturation at the sixth carbon atom from the methyl end of 
the chain. 
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Both linoleic and alphalinoleic acids are synthesized only by 
plants, but both can be further desaturated and elongated in animals. 
In humans linoleic acid is rapidly converted to arachidonic acid, 
whereas elongation and desaturation of alphalinoleic acid occurs 
very slowly to yield the n-3 PUFAs~EPA and DHA. Some plant oils such 
as soybean and linseed oil contain appreciable amounts of alpha­
linoleic acid but the conversion to EPA and DHA is very selective and 
in small quantities (Glomset, 1985). Marine phytoplankton and zoo-
plankton, on the other hand, are rich sources of the n-3 PUFAs and 
are sources of abundant EPA and DHA to other marine animals (Tinoco, 
1982). Therefore, a diet containing fish might provide more EPA and 
DHA than that formed from alphalinoleic acid which is consumed by 
vegetarians. From a health perspective eating fish rich in EPA and 
DHA might provide protection against CHD. 
III. Effects of n-3 PUFAs on Plasma Lipids 
Several controlled feeding trials have been conducted using 
both normo- and hyperlipidemic subjects. This review is organized 
according to the form in which n-3 PUFAs were fed. Diets used for 
most human studies included those supplemented with (1) fish oil, 
(2) a combination of fatty fish and oil, or (3) fatty fish. The 
results are summarized with respect to plasma lipid profiles in 
normolipidemics (Tables 1-4) and hyperlipidemics (Tables 5-7). 
The main findings of all feeding studies conducted in normo-
lipidemics are summarized in Table 1. The most consistent finding 
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Table 1 
Main Findings of n-3 PUFA Feeding Studies Conducted in Normo-
lipidemics 
Parameter 
Number of 
Studies That 
Measured 
Parameter 
Number of 
Studies That 
Show a 
Decrease 
Number of 
Studies That 
Show an 
Increase 
Total - TG 19 16 
Total Cholesterol (C) 17 7 
HDL-C 17 1 8 
LDL-C 9 4 1 
VLDL-C 4 
I 
3 1 
(16 of 19 studies) has been an impressive reduction in plasma TG 
levels. The impact on total cholesterol and lipoprotein cholesterol 
fractions has been less consistent and appears to be more dependent 
upon the amount of n-3 PUFAs consumed and length of the period over 
which the n-3 PUFA source was fed. The reported effects of the n-3 
PUFAs on the lipoprotein cholesterol fractions are to lower those 
plasma fractions that are associated with high CHD risk, namely, 
total, LDL and VLDL. Interestingly, n-3 PUFAs fed at high levels 
appear to increase HDL-cholesterol, one of the few dietary factors 
that has such an effect. However, one difficulty in comparing 
results across studies is the ability to translate the food item con­
sumed into a meaningful level of n-3 PUFAs. 
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Results of the studies that supplemented diets with fish oils 
are presented in Table 2. Some studies have used fish oils isolated 
from salmon flesh and cod liver. MaxEPA is a commercially prepared 
fish oil concentrate that is rich in EPA. It is a popular fish oil 
supplement and has also been used in many intervention trials (Herold 
& Kinsella, 1986). A reduction in plasma TG levels as a result of 
fish oil supplementation was observed in all of these studies. A 
threshold response effect of n-3 PUFAs on plasma TG was observed by 
those investigators who fed the fish oils at several levels 
(Brongeest-Schoute, van Gent, Luten, & Reuter, 1981; Sanders & 
Roshanai, 1983; von Schacky, Fischer, & Weber, 1985). Brongeest-
Schoute et al. (1981) found a significant reduction in plasma TG when 
8.2 g of n-3 PUFAs were consumed per day for four weeks. Amounts 
such as 1.4 g, 2.3 g and 4.1 g of n-3 PUFAs per day were not suffi­
cient to significantly reduce plasma TG. Von Schacky et al. (1985) 
also found significant reductions in plasma TG level of normolipidemic 
subjects fed the highest level (40 ml) of cod liver oil. 
A more prominent threshold effect can be seen with respect to 
plasma cholesterol when individuals were fed increasing amounts of 
MaxEPA. Five healthy male subjects consumed 5, 10 and 20 g of MaxEPA 
per day in a random order for three-week periods (Sanders & Roshanai, 
1983). Each experimental period was separated by a rest period of at 
least six weeks. The results revealed that a significant hypo-
cholesterol emic effect was observed only when subjects consumed 20 g 
of MaxEPA per day. Diets supplemented with 5 and 10 g of MaxEPA per 
day were unable to significantly lower the cholesterol levels. 
Table 2 
Suimiary of Effects of Fish Oils on Plasma Lipids in Nonnolipidanic Subjects 
Amount Duration 
Diets Fed of Diet 
Reference Compared to Per Day (Weeks) 
Saynor & Verel 
(1980) 
Brongeest-Schoute, 
van Gent, Luten, 
& Reuter (1981) 
Sanders, 
Vickers, & 
Haines (1981) 
Sanders & 
Hochland (1983) 
Sanders & 
Roshanai (1983) 
Illingworth, 
Harris, & Connor 
(1984) 
Nestel, Connor, 
Reardon, Connor, 
Wong, & Boston 
(1984) 
Customary 
1 g olive oil 
oil 
Customary 
10 g olive/ 
corn oil 
20 ml 
linseed oil 
Customary 
30-40% fat 
3OS energy 
from safflower 
oil 
20 ml 
MaxEPA oil 
1.4 g n-3 RJFA 
2.3 g n-3 PUFA 
4.1 g n-3 PUFA 
8.2 g n-3 PUFA 
20 ml 
cod liver oil 
10 g Max EPA 
011 
MaxEPA oil 
5 g 
10 g 
20 g 
120 g 
salmon oil 
(30-40% fat) 
(24 g n-3 PUFAs) 
30% energy 
as MaxEPA oil 
mq/100 ml 
75 Total-C— USC=C 7CTOT 
35%^ NSD 22% f - -
NSD NSD NSD NSD NSD 
NSD NSD NSD NSD NSD 
NSD NSD NSD NSD NSD 
39% NSO NSD NSD 4 
22%^ NSD 9%t - -
J- NSD 1- - -
14% J* NSD NSD 
23% 4s NSD NSD _ 
32%i, 9%^ 31%* -
43%^ 23%4- NSD 20% 4' -
* I J, 
Amount Duration 
Diets Fed of Diet mg/100 ml 
Reference Compared to ter Day (Weeks) T5 Total-C HDL-C LDL-C TLDL-C 
Sanders & 
Mistry (1984) 
Customary 10 gm 
MaxEFA 
011 
3 
5 
8 
14 
•Is 
<1* 
4, 
-
t
i
l
l
 
1 
1 
1 
1 
Von Schacky, 
Fisher, & Weber 
(1985) 
Customary cod liver oil 
10 ml 
20 ml 
40 ml 
20 ml 
4 
4 
4 
8 
NSD 
NSD , 
66% <1» 
NSD 
NSD 
NSD 
NSD 
NSD 
NSD 
NSD 
NSD 
NSD 
Sullivan, Sanders, 
Trayner, & 
Thompson (1986) 
Customary 15 g 
MaxEPA oil 
2 
4 
8 
* 
ir 
NSD 
NSD 
NSD : : : 
NSD = Not statistically different 
- = Not measured 
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Changes in HDL-cholesterol concentration are observed only at 
the highest doses of fish oil. A significant increase in HDL levels 
was observed when 20 g of MaxEPA was ingested by 23- to 30-year-old 
healthy volunteers for three weeks (Sanders & Roshanai, 1983). Saynor 
and Verel (1980) also reported that 20 ml of MaxEPA oil per day was a 
sufficient amount to produce an increase in HDL-cholesterol level. 
The same amount, however, failed to reduce total plasma cholesterol 
levels. 
The effect of fish oil or n-3 PUFAs on VLDL-and LDL-cholesterol 
has not been extensively investigated in human subjects. The amount 
of fish oil required to demonstrate an observed difference in LDL and 
VLDL levels appears to be similar to the level required for total 
cholesterol. The study by Nestel, Connor, Reardon, Connor, Wong, and 
Boston (1984) yielded conflicting results—an increase in LDL- and 
VLDL-cholesterol and a decrease in HDL-cholesterol. The level at 
which the n-3 PUFAs were provided is much higher than in any of the 
other studies; approximately 85 g of fish oil were consumed daily 
assuming that the diet provided 200 Kcal. Intakes at this level 
might possibly avoid the usual metabolic pathways for lipoprotein 
metabolism. 
In summary, it appears that the minimum amount of MaxEPA oil 
that is required to significantly impact on the plasma and lipoprotein 
cholesterol levels is at least 20 g per day. However, a much lower 
level of n-3 PUFAs (10 g of MaxEPA oil) is sufficient to significantly 
reduce the plasma TGs. 
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Those studies that have fed a fatty fish in combination with a 
fish oil supplement as a source of n-3 PUFAs have generally provided 
the n-3 PUFAs at much higher doses than in those studies that fed the 
fish oil alone (Table 3). The results have consistently shown a 
significant decrease in total TG and total-, LDL- and VLDL-cholesterol 
(Harris & Connor, 1980; Harris, Connor, & McMurry, 1983). However, 
these studies have failed to demonstrate any increase in HDL-
cholesterol. 
Studies in which fatty fish has been used as a source of n-o 
PUFAs (Table 4) need to be interpreted in light of both the amount of 
fish consumed and the duration of the treatment. Consumption of 200 g 
mackerel per day for three weeks resulted in significant decreases in 
plasma TG and total cholesterol (Von Lossonczy, Reuter, Brongeest-
Schoute, van Gent, & Hermus, 1978). A higher amount (500-800 o 
mackerel per day) when fed for only one week, however, failed to 
reduce the plasma TG and total cholesterol (Siess, Scherer, Bohlig, 
Roth, Kurzmann, & Weber, 1980). These results indicate that consump­
tion of fish even at high levels for one week is too short a period 
to observe any changes in plasma lipids. It is usually assumed that 
3-4 weeks are required to demonstrate an effect of diet on lipoprotein 
cholesterol metabolism. Feeding levels as low as 28-85 g of fatty 
fish per day for three months were associated with a significant 
decrease (6%) in plasma TG but did not cause a decrease in any other 
plasma lipids (Fehily et al., 1983). These authors suggested that an 
effect of consumption of such low amounts might be manifested only 
Table 3 
Summary of Effects of Fatty Fish and Fish Oil on Plasma Lipids in Normolipidemic Subjects 
Diets 
Amount 
Fed 
Duration 
of Diet mq/100 ml 
Reference Compared to Per Day (Weeks) TG Total-C HbL-C LDL-C VLbL-t 
Harris & Connor 
(1980) 
Customary diet salmon flesh + 
Max EPA oil 
4 41% J/ 17%| NSD 15%4' 40%^ 
Goodnight, Harris, 
& Connor (1981) 
Customary 
45% fat diet 
500 mg cholesterol 
1 lb salmon flesh + 
60-90 ml MaxEPA oil 
(10 g n-3 PUFA) 
4 - - -
Harris, Connor, & 
McMurry (1983) 
Saturated fat 
control diet 
vegetable oil 
control diet 
(40% fat) 
1 lb salmon flesh + 
3-6 T MaxEPA oil 
(20-29 g n-3 PUFA) 
(40% fat) 
4 38%^ 14%^ NSD 16%4r 38%^ 
NSD = Not statistically different 
- = Not measured 
Table 4 
Suranary of Effects of Fatty Fish on Flasma Lipids in Normolipidemic Subjects 
Amount Duration 
Diets Fed of Diet mg/100 ml 
Reference Compared to Fter Oay (Weeks) TE Total-C HDL-C LbL-C VLDL-C 
VonLossonczy, 
Reuter, Brongeest-
Schoute, van Gent, 
& Hernus (1978) 
150 g cheese 200 g mackerel 3 35%^ 7.5%4r 7%f 
(Females 
only) 
-
Siess, Scherer, 
Bohlig, Roth, 
Kurtzman, & 
Weber (1980) 
Customary 500-800 g mackerel 
(7-11 g n-3 FUFA) 
1 NSD NSD 
Fehily et al. 
(1983) 
Customary 28-85 g fatty fish 12 NSD USD NSD 
Singer, Jaeger, 
Wirth, Naumann, 
Zimontkowski, 
Hazda, & 
Groedicke (1983) 
Customary before 
mackerel feeding 
Customary 3 months 
after mackerel 
feedi ng 
280 g mackerel 
280 g herring 
2 
2 
473:^ 
NSD 
7%^ 
NSD 
NSD 
NSD 
NSD 
NSD 
Atkinson, Wheeler, 
Mendelsohn, Pienaar, 
& Chetty (1987) 
Customary 750 g trout 
(meat free diet) 
2 
4 
NSD 
NSD 
NSD 
NSD 
* 
NSD -
Spiller, Jensen, & 
Seal a (1987) 
Customary 100 g fish 
300 g fish 
600 g fish 
4 
4 
4 
4, NSD 
NSD 
NSD 
f 
f 
NSD 
. NSD 
NSD 
NSD = Not statistically different 
- = Not measured 
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when consumed for longer periods of time, and that these amounts might 
be insufficient to impact on plasma cholesterol. 
Consumption of fatty fish has also produced variable effects on 
HDL-cholesterol levels. Consumption of 200 g mackerel (2-3 g n-3 
PUFAs) per day has been shown to significantly increase HDL-
cholesterol and decrease total cholesterol (Von Lossonczy et al., 
1978). Whereas greater amounts of mackerel (280 g per day) when con­
sumed for a shorter period, i.e., two weeks failed to bring about a 
significant increase in HDL-cholesterol although total cholesterol was 
significantly reduced (Singer, Jaeger, Wirth, Voigt, Naumann, 
Zimontkowski, Hajdu, & Goedicke, 1983). In a recent study the supple­
mentation of a typical western diet of 28 normolipidemic men with 
fish yielding 1, 3 and 6 g of n-3 PUFAs per day for one month signifi­
cantly increased HDL-cholesterol at all levels of n-3 PUFAs (Spiller, 
Jensen, & Scala, 1987). 
None of the feeding studies conducted observed that supplements 
of fatty fish as a source of n-3 PUFAs had any significant impact on 
LDL-cholesterol levels. The effect of fatty fish on VLDL-cholesterol 
in healthy subjects has not been extensively studied. 
The main findings of all feeding studies conducted in hyper-
lipidemics are summarized in Table 5. As in normolipidemics the most 
consistent effect was in a reduction of total TG. However, a decrease 
in total cholesterol and increase in HDL-cholesterol is evident in the 
majority of studies. The differences observed between normo- and 
hyperlipidemics appears to be in the LDL fraction. In normolipidemics 
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Table 5 
Main Findings of n-3 PUFA Feeding Studies Conducted in Hyperlipidemics 
Parameters 
Number of 
Studies That 
Measured 
Parameter 
Number of 
Studies That 
Show a 
Decrease 
Number of 
Studies That 
Show an 
Increase 
Total TG 10 10 
Total-C 8 7 
HDL-C 5 1 4 
LDL-C 3 2 2 
VLDL-C 3 3 
if there is an observed effect in the LDL fraction it is a lowering 
effect and in hyperlipidemics the effect is inconsistent and dependent 
upon the hyperiipidemia disorder under observation. The reduction in 
total cholesterol appears to be contributed from VLDL rather than LDL 
fraction. 
Studies conducted with hyperlipidemic subjects have generally 
used either pure fish oil or fish supplemented with fish oils; results 
from which are presented in Tables 6 and 7. In general, feeding 
experiments with hyperlipidemic subjects have resulted in impressive 
reductions in plasma lipids. The greatest plasma lipid reductions 
were reported in an interventional trial in 20 subjects with hyper-
lipidemia (type lib or type V) (Phillipson, Rothrock, Connor, Harris, 
& Illingworth, 1985). The study compared the effect of three diets 
that differed in fatty acid composition and fat content; a standard 
Table 6 
Sunmary of Effects of Fish Oils on Plasma Lipids in Hyperlipidemic Subjects 
Reference 
Diets 
Compared to 
Amount 
Fed 
Per Day 
Duration 
of Diet 
(Weeks) TG" 
mq/100 ml 
Total-C CEI^T VLDL-C 
Harris, Connor, 
Illingworth, & 
Foster (1984) 
Sanders & Mistry 
(1984) 
Saynor (1984) 
Saynor, Verel, & 
Gillott (1984) 
Woodcock, Smith, 
Lambers, Morris, 
Jones, Galloway, 
Greaves, & Preston 
(1984) 
Phillipson, 
Rothrock, Connor, 
Harris, & 
Illingworth (1985) 
75% high CHO 
diet 
corn/olive oil 
corn/olive oil 
Cu stomary 
10 g corn/olive 
011 mix 
150 mg cholesterol 
20-30% low fat 
diet 
Type lib 
5% fat diet 
<100 mg 
cholesterol 
Type V 
50 g MaxEPA 
oil in 75% 
CHO diet 
10 g MaxEPA 
011 
10 g MaxEPA 
011 
20 ml MaxEPA 
oil 
10 g MaxEPA 
011 
1 
3 
5 
8 
14 
4 
12 
26 
38 
52 
104 
salmon oil diet 
(20 g n-3 FUFA) 
(30% fat diet) 
(325 mg cholesterol) 
salmon oil diet 
(20 g n-3 FUFA) 
(30% fat) 
(350 mg cholesterol) 
61% 
* 
48% 1 8%4> 
37% J' NSD 
36% J' 2%^ 
41%^ 4%^ 
38% b NSD 
37%^ NSD 
41%-J' 5%^ 
27%^ NSD 
64%^' 
Type lib 
79%4> 
Type V 
27%^ 
Type lib 
48%^ 
Type V 
T 
t 
T 
17%f 
10% ^ 
7%t 
10% f 
NSD 
NSD 
14%t 
17%^ 12%i 73% 4* 
Type lib Type lib Type lib 
NSD 48%t 71%^ 
Type V Type V 
00 
Diets 
Amount 
Fed 
Duration 
of Diet mq/100 ml 
Reference Compared to Per Day (Weeks) tG Total-C HDL-C LDL-C VLDL-C 
Simons, Hickie, 
& Balsubramaninm 
6 g olive oil 
placebo 
6 g MaxEFA 
oil 
12 282^ 
Type lib 
4lU 
NSD - - -
16 g olive oil 
placebo 
16 g Max EPA 
oil 
12 
Type IV 
58?^ 
Type V 
34%^ 
Type V 
f > % f  7%* 42 
Sullivan, Sanders, 
Traynor, & 
Thompson (1986) 
Customary 15 g MaxEFA 
oil 
4 48%^ 
NSD = Not statistically different 
- = Not measured 
Table 7 
Summary of Effects of Fatty F1sh and Fish Oil on Plasma Lipids in Hyperlipidemic Subjects 
Amount Duration 
Diets Fed of Diet mg/100 ml 
Reference Compared to Per Day (Weeks) Tg Total-C HDL-C LDL-C VLDL-C 
Harris & 
Connor (1980) 
Customary salmon flesh + 
Max EPA oil 
4 67%^ 20%^ -
Riillipson, 
Harris, & Connor 
(1981) 
100 mg 
cholesterol 
20% low fat diet 
Type lib 
5% fat eucaloic 
Type V 
salmon and 
salmon oil with 
fat content of 
20-50% of total 
calories 
1 1 / 3 - 4  
1 1 / 2 - 4  
65%^ 
Type lib 
50%^ 
Type V 
24% i 
Type lib 
13% J' 
Type V 
15%^ 86%^ 
Type lib Type lib 
104%^ 50% 1/ 
Type V Type V 
NSD = Not statistically different 
- = Not measured 
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low-fat control diet, a fish (salmon) oil diet (20 g n-3-PUFAs per 
day) and a vegetable oil diet (n-6 PUFA). The control diet was 
lower in cholesterol than the other two diets. In both groups of 
subjects (those with type lib and those with type V hyperlipo­
proteinemia) the fish oil diet resulted in pronounced reductions of 
plasma cholesterol, TG and VLDL. It has been postulated that the 
mechanism for the observed changes was a decreased production of VLDL 
rather than an increase in catabolism of VLDL. This decreased pro­
duction of VLDL was consistent with the observed lipid changes of a 
considerable decrease in TG and greater reduction in VLDL than in 
LDL- or HDL-cholesterol. Consistent reduction in elevated plasma TG 
levels by feeding 5, 10, 15 and 20 ml of MaxEPA oil per day for 
periods ranging from 1 month to 24 months were observed by Saynor 
(1984), Saynor, Verel, and Gillott, (1984), Woodcock, Smith, Lambert, 
Morris, Jones, Galloway, Greaves, and Preston (1984), Sullivan, 
Sanders, Trayner, and Thompson (1986), and Simons, Hickie, and 
Balasubramaniam (1985) have also observed significant reductions in 
plasma TG of both type lib and type V hyperlipi demies when 6-16 g of 
MaxEPA oil were fed for three months. 
Fish oils have also been reported to reduce the elevated 
plasma TG and VLDL levels accompanying a high carbohydrate diet 
(Harris, Connor, Illingworth, & Foster, 1984). Type V hyperlipidemic 
individuals with abnormally low LDL levels have shown increases in 
their mean LDL-cholesterol levels after consuming fish oil containing 
diets. This observation was also accompanied by reduction in VLDL-
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cholesterol and VLDL-TG levels which suggested an improved conversion 
of VLDLs (Phillipson, Rothrock, Connor, Harris, & Illingworth, 1985). 
The cholesterol lowering effect of fish oils, however, has not 
been reported by all the studies that have used fish oils to correct 
hyperlipidemia. Saynor (1984) and Saynor et al. (1984) have observed 
reductions in cholesterol levels of hyperlipi demies at dosages of 10 
and 20 g MaxEPA oil per day, whereas, Woodcock et al. (1984) failed 
to reduce total cholesterol in hyperlipidemics fed 10 g of MaxEPA per 
day. Simons et al. (1985) have shown a reduction in plasma 
cholesterol in type V hyperlipidemics when 16 g of MaxEPA was fed per 
day for three months. 
Studies with hyperlipidemics have produced effective results 
with respect to HDL-cholesterol. Most studies have found an increase 
in HDL-cholesterol in those individuals supplemented with fish oil 
(Sanders & Mistry, 1984; Saynor, 1984; Saynor et al., 1984; Simons 
et al, 1985). Only Phillipson et al. (1985) found reductions in 
HDL-cholesterol for type lib hyperlipidemics but no significant 
difference in type V hyperlipidemics consuming a salmon oil diet. 
The effect of fish oils on LDL- and VLDL-cholesterol in hyper-
lipidemics has not been extensively studied. Phillipson et al. (1985) 
have reported a reduction in LDL-cholesterol of type lib hyper-
1ipidemics but an increase in LDL-cholesterol of type V hyper-
lipidemics. A reduction in VLDL, however, is consistently seen across 
studies (Phillipson et al, 1985; Simons et al., 1985). Thus, it 
appears that the effect of fish oils on total cholesterol and 
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cholesterol in different lipoprotein fractions is variable. The type 
of hyperlipidemia might influence the effect of n-3 PUFAs. 
The two clinical trials with hyperlipi demies that have used 
fatty fish and fish oils have reported significant reductions in 
plasma TG, total cholesterol, LDL- and VLDL-cholesterol (see Table 7) 
(Harris & Connor, 1980; Phi 11i pson et al., 1981). Phi 11i pson et al. 
(1981) fed salmon flesh in combination with salmon oil and the sub­
jects appeared to benefit from eating fatty fish usually contrain-
dicated in type lib and type V hyperlipoproteinemia. Salmon contains 
approximately 10% total fat by weight and is generally restricted in 
diets of persons with hypertriglyceridemia. There are no studies 
that have attempted to study the effect of fish alone in hyperlipi-
demics. 
IV. Effects of n-3 PUFAs on Platelet Function 
Dyerbert and Bang (1982) conducted epidemiological studies in 
Greenland Eskimos and observed that this population group exhibited 
prolonged bleeding time and reduced platelet aggregation as compared 
to their Danish counterparts. The role of dietary marine fatty acids 
on platelet function might explain, in part, their low incidence of 
coronary heart disease. 
There appears to be several mechanisms by which n-3 PUFAs might 
be involved in altered platelet function. Their role might be 
explained, in part, by alterations in prostaglandin synthesis. 
Arachidonic acid (AA) is the major precursor of the prostaglandins 
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(Figure 1). Most AA is formed from dietary linoleic acid (LA) by 
sequential desaturation and elongation; it is then acted upon by 
cycloxygenase to form the endoperoxides (PGG2 and PGH2). These 
endoperoxides are the intermediate compounds in prostaglandin 
synthesis. In platelets the endoperoxides are transformed into 
thromboxane A2 (TXA2) which has strong platelet aggregating and 
vasoconstrictive effects. In vascular endothelium the endoperoxides 
are converted to prostacyclin (PGI2) which is a vasodilator and a 
potent inhibitor of platelet aggregation. The balanced antagonistic 
effect of TXA2 and PGI2 regulate the initial steps of blood clotting. 
It is hypothesized that increased dietary n-3 PUFAs should 
increase their levels in platelet phospholipids which in turn would 
allow them to complete effectively with AA for cycloxygenase. Altera­
tions in prostaglandin synthesis should result in a reduction of 
platelet aggregation and an increase in bleeding time. Indeed, 
reduced platelet aggregation and increased bleeding time were observed 
in the study conducted by Fischer and Weber (1984) in the n-3 PUFA 
supplemented groups as compared to nonsupplemented controls. Others 
have also reported increased EPA and DHA levels in platelet lipids 
following the supplementation with n-3 PUFAs (Goodnight, Harris, & 
Connor, 1981; Sanders, Naismith, Haines, & Vickers, 1980). These 
increases were accompanied by decreased levels of LA and AA in plate­
let lipids. Related effects, such as reduced platelet aggregation 
and prolonged bleeding time, have also been reported and could be 
attributed to altered prostaglandin synthesis (Herold & Kinsella, 
1986). 
Dietary Linoleic Acid 
Tissue 
Phospholipids desaturase 
EPA 
Linoleic Acid 
Phospholipase 
elongase 
Arachidonic 
Acid 
cyclooxygenase Prostanoids 
(PCD3PCE3TXA3) EPA 
synthetase 
. Endoperaxidas 
(endothelium) (PGG2-PGH2) (platelets) 
Prostacyclin 
(PGIa) 
Thromboxane 
(TXAa) 
Prostaglandins 
(PGEaiPGFa, etc.) 
EPA 
Figure 1: Roles of Linoleic Acid and Arachidonic Acid in 
Prostaglandin Synthesis. 
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Evidence also suggests that EPA might be converted to PGIg 
which is an effective antiaggregatory agent (Fischer & Weber, 1984). 
The major urinary metabolite of endogenous prostaglandin Ig was 
present in human subjects consuming diets high in EPA either as a cod 
liver oil (4 g EPA daily) or as mackerel flesh (10-15 g EPA daily). 
Another possible effect of n-3 PUFAs has been reported by Lee, 
Hoover, Williams, Sperling, RaValese, Spur, Robinson, Corey, Lewis, 
and Austin (1985). These researchers hypothesized that n-3 PUFAs also 
effect the archidonic acid metabolic pathway leading to leukotriene 
formation. Omega-3 PUFAs cause a reduction in leukotriene gene­
ration with loss of functional competence as assessed by endothelial 
cell adherence. Endothelial cell adherence enhances the adherence of 
monocytes to the arterial wall and the migration to the internal 
layer where they are transformed into macrophages which accumulate 
lipids and stimulate smooth muscle cell profiferation (Ross, Bowen-
Pope, Raines, & Faggiotto, 19o2). Eicosapentaenoic acid and DHA are 
known to form leukotriene Bg which is different from leutotriene 
and is known to reduce monocyte adherence. This action might help to 
reduce the atherosclerotic lesions (Glomset, 198b). 
Lower blood viscosity is also another parameter under investi­
gation because it is believed to be a measure of platelet stickiness 
(Lee, Hoover, Williams, Sperling, RaValese, Spur, Robinson, Corey, 
Lewis, & Austin, 1985). A study of Japanese fishermen showed that 
higher concentrations of ADP were required to result in half-maximal 
aggregation than in a group of farmers (Kabayashi, Hirai, Terano, 
Hamazaki, & Kumagai, 1981). The researchers believed that even small 
amounts (2.5 g) of n-3 PUFAs might lower whole blood viscosity and, 
consequently, alter platelet aggregation. 
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CHAPTER III 
METHODOLOGY 
Study Design 
The present study was designed to assess the effects of n-3 
PUFA consumption on various plasma lipid levels and prothrombin time 
in hyperlipidemic men. A Latin square design (Figure 2) which allowed 
adjustment for any carry-over effect of previous treatment into the 
succeeding period without separating the three test periods by a wash­
out phase was employed. Three dietary treatments were evaluated: the 
men's customary and a food source of n-3 PUFA fed at two levels. In 
Figure 2, high (H) and moderate (M) fish diets and customary (C) 
denote the three dietary treatments; the composition of the three 
experimental diets was as follows: 
H - 8 oz (225 g) of salmon consumed four times per week 
yielding approximately 900 g of salmon per week or 9 g 
of n-3 PUFA per week. 
M - 8 oz of salmon consumed two times per week yielding 
approximately 450 g of salmon per week or 4.5 g n-3 PUFAs 
per week. 
C - Customary AHA Phase I diet 
The phase I diet restricts total fat intake to 30% of 
total energy with approximately 10% of total calories from 
each of the following: monounsaturated fatty acids (MFAs), 
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SFAs and PUFAs, respectively, and which contains about 
TOO mg cholesterol per 1U00 calories (American Heart 
Association, 1986). 
Sequence 
Week Period 1 2 3 4 5 6 
1 
2 
3 1 H M C H M C 
4 
1 
2 
3 2 M C H C H M 
4 
1 
2 
3 3 C H M M C H 
4 
Figure 2: Experimental Design: Sequence of the Test Diets 
Each participant consumed all three diets but in a different 
sequence. Subjects were randomly assigned among six sequences. Each 
dietary treatment lasted for four weeks. 
Fasting blood samples were obtained at four points in the 
study, at the start and at the end of each dietary treatment phase. 
Each participant was requested to keep a food diary for four days 
during the last week of each treatment phase. At the end of H and M 
treatment phases of the study, a questionnaire was administered to 
obtain information on the acceptability of the fish provided in the 
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preceding four weeks (Appendix A). Data was also collected on smoking 
history, medication use, including aspirin, and/or any other anti­
coagulant and lipid lowering agents. 
Subjects 
Eighteen men between 45-65 years of age were selected from a 
pool of hyperlipidemic patients who were participants of a cardiac 
rehabilitation program at Wake Forest University in Winston-Salem, NC. 
Subjects were included if they met the following criteria: hyper-
lipidemic, no allergy to fish, did not regularly consume more than 
16 oz of fish per week, and were generally complaint to the AHA phase 
I diet. Dietary adherence to the AHA diet was assessed by asking 
eligible participants to keep a four-day food record prior to entry 
into the study. 
Only those subjects who had fasting plasma lipids either equal 
to or greater than the age and sex specific 75th percentile values for 
total cholesterol and TGs, observed in the prevalence study of the 
Lipid Research Clinics (LRC), were included (Appendix B) (U.S. Depart­
ment of Health and Human Services, 1980). Men were excluded if their 
body mass index (EMI) exceeded the value estimated to represent 40% 
overweight for men (Metropolitan Life Insurance Co., 1983). The 
experimental protocol was fully explained to each participant and an 
informed consent was obtained (Appendix C). 
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Diets 
The three different dietary treatments (Figure 2) were followed 
by all the participants. The fish was prepared, packed and distrib­
uted weekly to the subjects in the morning after the completion of 
their exercise program at the center. They were instructed to 
substitute the fish for an entree at lunch or dinner. 
Several fish recipes were pretested using the staff of the 
Cardiac Rehabilitation Program as the evaluators. The testers were 
asked to. rank the recipes for their taste, appearance, portion size, 
and overall acceptability on a four-point scale. The recipes that 
scored excellent, good, and average were included in the study. All 
recipes used in the study are presented in Appendix D. 
At the start of a new dietary treatment individualized guide­
lines were provided to each participant to promote adherence to the 
new diet. Participants were asked to keep a record of any leftovers 
of the fish on a weekly basis. They were also requested to keep a 
diary of all foods consumed during four days (2 week days and the 
weekend) of the last week of each treatment phase. A diet record 
designed by the Cardiac Rehabilitation Program was used because it was 
familiar to the participants. 
Analytical Methods 
Dietary Analysis 
A diet analysis software program, the Nutritionist II, was 
employed to analyze the four-day food record for cholesterol, total 
32 
calories, total and percent of calories from protein, carbohydrate, 
fat, saturated and polyunsaturated fatty acids. To ensure that the 
investigator was assigning codes to foods in a manner similar to 
dietitians at the Cardiac Rehabilitation Center, six food records were 
coded by each individual and the codings reviewed. Adherence to diet 
and consistency of dietary behavior throughout the study period were 
ascertained from the dietary analysis. 
A Keys' score was used as a means of describing the effect of 
dietary pattern on serum cholesterol. The score is based on saturated 
(sat) and polyunsaturated (polyunsat) fat, cholesterol and calories in 
the daily diet (Anderson, Jacobs, Foster, Hall, Moss, Majonnier, & 
Blackburn, 1979). 
Keys' formula: 
dietary index = 2.70 (sat fat) - 1.35 (polyunsat fat) + 
1.52 s/ 1000 dietary C/total energy 
where both saturated fat and polyunsaturated fat are 
calculated as a percent of total calories. 
Blood Collection 
Fasting blood samples (minimum of a 12-hour fast) were drawn 
at baseline and weeks 4, 8 and 12 into vacutainers containing either 
ethylenediaminetetracetic acid (EDTA) or sodium citrate as anticoagu­
lants. The whole blood was centrifuged for 15 minutes at 2500 rpm 
in order to separate the plasma from the red blood cells. An aliquot 
of fresh citrated plasma was used for prothrombin time. The remaining 
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citrated plasma and plasma collected in EDTA were stored in poly­
ethylene vials and frozen at -20°C. 
Plasma Lipid Analysis 
Lipid profiles including total TGs, total-, KDL- and LDL-
cholesterol were determined for each sample. Total TG levels were 
assessed by the colorimetric enzymatic assay based on the method of 
Bucolo and David (1973). A Sigma diagnostics kit obtained from Sigma 
Inc., St. Louis, MO was used for this analysis. Total cholesterol and 
HDL-cholesterol were determined by the enzymatic method described by 
Allain, Poon, Chan, Richmond, and Fu (1974). The HDL fraction was 
isolated by using an HDL-precipitating agent obtained from Sigma Inc., 
St. Louis, MO. The LDL fraction was calculated using the following 
formula: 
LDL-C = total-C - (total-TG + HLD-C) 
5 
The analytical methods were standardized by using a lipid con­
trol containing normal levels of TGs and cholesterol; the normal lipid 
control was obtained from Sigma Inc. To monitor reliability of test 
results, frozen aliquots of blood drawn from the investigator at the 
beginning of the study were assayed for lipids with each group of 
samples. 
Prothrombin Time 
Prothrombin time was measured using fresh citrated palsma with 
an assay kit purchased from Sigma Inc. The kit was based on the 
method described by Quick (1966). The method was standardized by 
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using the normal plasma control obtained from Sigma Inc. The normal 
plasma control was also included with each group of samples to monitor 
reliability of test results. 
Statistical Analysis 
The Latin square design that was employed allowed for the 
assessment of residual (carry-over) effects of each of the three 
dietary treatments (Cochran & Cox, 1968). An analysis of variance-
general linear models (6LM) procedures of the Statistical Analysis 
Systems (SAS, 1985)—was employed to examine the adjusted direct 
effects and residual effects of each of the three dietary treatments. 
There was a significant residual effect for only one variable, total 
TG. The direct effect mean adjusted for the residual effect was 
calculated according to the method developed by Williams (1949). 
A simpler design was employed to further examine the dietary 
treatment effect on the other variables for which there existed no 
residual effect, namely, total-, HDL- and LDL-cholesterol, and 
prothrombin time. The design selected blocked on individuals and 
period. This design was chosen in preference to a repeated measures 
design since it more closely resembled the original design by taking 
into account an ordering effect. If the dietary treatment effect was 
deemed significant, then differences between individual means were 
examined. The a priori comparisons of interest were those that 
involved comparing the two levels of fish consumption to the control 
mean. 
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A one-way analysis of variance (ANOVA) was performed to assess 
the effects of dietary treatment on composition of the diets consumed. 
If the dietary treatment effect was deemed significant, then differ­
ences between individual means were examined. Again, the a priori 
comparisons of interest were those that involved comparing the two 
levels of fish consumption to the control mean. 
Analysis of covariance was performed to determine if the effect 
of dietary treatment remained after adjusting for potential con-
founders. Potential confounders that were examined included those 
variables for which there was a significant treatment effect and any 
additional covariates which included those dietary variables for which 
there was a significant correlation between the nutrient and blood 
outcome measure. Some dietary data was missing for two individuals 
and values were assigned to replace the missing values; the value used 
was the estimated mean dietary value for the treatment within the same 
period. The potential confounders were assessed as potential effect 
modifiers by including their interaction with treatment in the full 
model. All such two-way interactions were assessed together using a 
chunk test. Only covariables that were determined to add signifi­
cantly to the model were reassessed individually as effect modifiers 
by adding a two-way interaction term. None of the covariables were 
found to be effect modifiers. 
Differences in responses to items on the acceptability 
questionnaire between the two frequencies of salmon consumption were 
compared using the chi-square statistic. 
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CHAPTER IV 
RESULTS 
Baseline characteristics (means and standard error [SE]) of the 
six groups prior to randomization to treatment groups are presented 
in Table 8. There were no statistically significant differences noted 
in any of the measured characteristics among the six groups. Mean age 
of men in each group ranged from 51 to 61. The baseline values for 
plasma TGs and total cholesterol indicated that the subjects met the 
eligibility criteria of being hyperlipidemic. Triglyceride values 
across six groups were more variable than for total cholesterol 
levels; the mean TG level for Group 2 was the highest among all 
groups (433.6 mg per dl). This elevated TG level could be attributed 
to a single individual in Group 2. This particular individual had a 
baseline TG level of 786 mg per dl. The baseline BMI values of all 
subjects were under the estimated value representing 40% overweight 
value for men. 
The subjects were also assessed for their compliance to the AHA 
Phase I diet which recommended 30% of total calories from fat. The 
percent of calories from total fat as shown in Table 8 indicated that 
subjects were generally compliant to 30% calorie AHA diet. A Keys' 
score was computed as a means of describing the effect of differences 
in diet on serum cholesterol. 
Table 8 
Baseline Characteristics of the Six Groups Mor to Randomization to Treatment 
Characteristics X 
1 
SE X 
2 
SE X 
3 
SE X 
4 
SE X 
5 
SE 
6 
X SE 
Age (years) 55.0 ± 4.1 56.7 ± 39.0 55.0 ± 3.5 61.3 ± 0.9 51.0 ± 4.5 55.0 ± 4.0 
Triglyceride (mg/dl) 273.2 ± 59.8 433.6 ± 179.8 242.3 + 13.7 227.1 ± 30.6 194.8 ± 10.1 313.3 ± 34.5 
Total-C (mg/dl) 244.2 ± 9.2 291.7 ± 24.3 247.0 ± 15.5 248.0 + 10.8 256.1 + 12.5 265.6 ± 12.8 
HDL-C (mg/dl) 27.7 ± 4.5 36.6 ± 3.6 34.9 ± 4.0 30.8 ± 6.6 46.5 ± 1.8 30.6 ± 3.3 
LDL-C (mg/dl) 161.9 ± 10.3 168.4 ± 15.4 163.6 ± 14.0 171.7 ± 10.7 170.6 ± 11.7 172.4 ± 9.7 
FTothromb Time (PT) 
(seconds) 
20.0 + 2.8 20.7 + 2.0 20.7 ± 3.7 19.6 ± 1.9 21.2 + 0.2 22.5 ± 2.8 
BM1 26.7 ± 1.8 29.3 ± 0.9 25.0 ± 2.4 26.1 + 2.3 25.0 ± 1.9 26.3 ± 1.1 
Total Calories 
(Cal) 
1328.0 ± ; 229.0 1318.0 + 68.0 1424.0 ± 18.5 1315.3 ± 259.3 1233.7 ± 16.3 1847'.3 ± 250.0 
Keys' Score 25.6 ± .4.7 36.8 ± 5.1 33.5 ± 6.6 38.8 ± 5.0 33.3 ± 3.3 32.3 ± 4.6 
Total Fat (% Cal) 23.7 + 5.4 30.7 + 2.0 29.7 + 1.2 35.0 + , 0.6 25.3 ± 1.3 34.3 ± 2.0 
Cholesterol (mg) 146.0 ± 37.2 202.3 + 43.4 164.0 ± 11.8 171.3 + 7.7 118.7 + 20.9 196.0 ± 43.1 
X = mean 
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Individuals were randomly assigned to groups and then these 
groups were randomly assigned to treatment sequence within each Latin 
square. The Latin square design employed allowed for the assessment 
of carry-over effects of each of the three dietary treatments. There 
was only one variable, total TG, for which there was a significant 
residual (carry-over) effect. The original design allowed the estima­
tion of the treatment effect adjusted for the residual effect (written 
as the direct effect in the ANOVA table) (see Appendix E for ANOVA 
table). Total TG mean values for each treatment were adjusted for 
the residual effect according to the method by Williams (1949) and 
are presented in Table 9. There was no significant residual effect 
for the other parameters—total-, HDL- and LDL-cholesterol and 
prothrombin time (see Appendix E). In addition to the ANOVA per­
formed above, which included all individuals, an analysis was per­
formed with the removal of the individual in Group 2 who consistently 
had high TG values. Removal of the individual did not alter the 
ANOVA results. 
For those outcome variables for which there was no residual 
effect a simpler ANOVA design was used to assess treatment effect. 
Statistical analyses clearly demonstrated that there was a significant 
impact of dietary treatment on the outcome variables. Means and 
standard error of the variables of interest by treatment are pre­
sented in Table 10 (see Appendix F for ANOVA tables). The effect of 
treatment, i.e., feeding of supplementary salmon, appeared to be 
limited to the higher levels of feeding of salmon (4 time per week). 
Table 9 
Means and Standard Errors of Outcome Variables by Treatment 
Dietary Treatment^ 
Control Moderate High 
Parameters X" SE I SE X SE 
Triglycerides2'^ (mg/dl) 254.3 ±6.7 227.64 ±6.7 229.84 ± 6.7 
Total-C2 (mg/dl) 250.6 ± 7.0 241.44 ±7.3 236.64 ± 7.5 
HDL-C2 (mg/dl) 39.4 ±2.1 40.1 ±2.0 41.44 ±2.0 
LDL-C2 (mg/dl) 160.8 ± 5.8 155.9 ± 5.3 149.94 ± 5.7 
PT2 (seconds) 22.8 ± .8 23.6 ± .9 24.24 ± .7 
^Each value is the mean + standard error (SE) 
2 Significant treatment effect £ <.05 
3 Mean adjusted for residual effect according to method by Williams (1949) 
4 Significantly different from control mean; individual £ values set at <0.025 to maintain an 
overall alpha of 0.05 
CO to 
Table 10 
Dietary Variables-Means and Standard Errors by Treatment 
Parameters 
Control 
_X J>£ 
Dietary Treatment^ 
Moderate 
St 
High 
SE 
Energy (Kcal) 1476 ± 72.5 1338 ± 65.0 13602 + 63.9 
Total Fat^ (g) 55.8 ± 3.8 43.14 
+
i 
45.5 + 3.7 
SFA (g) 16.9 ± 1.4 12.8 ± 1.2 13.1 + 1.3 
Linoleic Acid (g) 8.7 ± 0.8 7.7 
CO o
 
+1 
8.3 + 0.8 
0 
Cholesterol (mg) 208.4 ± 16.9 174.2 ± 15.1 lbl.44 + 15.1 
3 Keys' Score 38.2 ± 1.9 32.74 ± 1.7 31.94 + 1.8 
Weight (lb)^ 132.7 ± 0.2 181.64 ± 0.2 CO
 
.—
i 
+ 0.2 
Hach value is the mean ± SE 
2 Adjusted for unequal cell size 
3 
Statistically significant treatment effect £ .06 
4 Significantly different from control mean; individual £ values set at <0.025 to maintain an 
overall alpha of U.Ob 
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Feeding salmon two times per week showed statistically significant 
beneficial effecgs only for total TG and total cholesterol. The 
maximum reduction in total cholesterol was seen at the highest level 
of salmon feeding (4 times per week), whereas TG levels showed maximum 
reduction at lower levels of salmon feeding (2 times per week). 
Beneficial effects of feeding salmon on HDL--an increase—and LDL-
cholesterol—a decrease—and prothrombin time—an increase—were seen 
only at the higher level feeding (4 times per week). It therefore 
appeared that feeding salmon four times per week was beneficial to all 
parameters under investigation, whereas reduced amounts of salmon 
(2 times per week) were only beneficial to total TG and total 
cholesterol. 
The question that remained to be answered was "Cound the effect 
be attributed to the increase in n-3 PUFA consumption or did the 
supplementation of salmon to the customary diet result in changes in 
other dietary factors?" Analysis of the dietary variables indicated 
that the composition of the diets consumed differed among the three 
dietary treatment groups (Table 10). Different nutrient consumption 
patterns were observed between the two frequencies of salmon feeding 
and the control diet. When salmon was fed twice a week, total fat 
content of the diet was significantly less than when a control diet 
was consumed. However, even though the feeding of salmon four times 
per week tended to increase fat consumption slightly above that 
observed during the moderate salmon feeding phase, dietary cholesterol 
intake was significantly reduced and the computed Keys' score was 
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lower than observed on the control diet. Body weights of men on the 
different treatment groups also differed. 
Results of the analysis of covariance, an attempt to control 
for differences in diet composition, are presented in Table 11. The 
analysis of covariance (ACOVA) tables for total-, HDL- and LDL-
cholesterol are presented in Appendix G. There remained a statisti­
cally significant effect of treatment for four variables—TGs, total-
and LDL-cholesterol and prothrombin time—even after adjustment for 
other dietary factors. The covariates listed added significantly to 
the model. None of the potential covariates made a significant con­
tribution to the total variance of models containing total TGs and 
prothrombin time. The Other lipid parameters, i.e., HDL- and LDL-
cholesterol, were analyzed for treatment effect after adjustments were 
made for the contribution of total and saturated fat as covariates. 
Effect on total cholesterol was also analyzed after adjustment for 
total and saturated fat and weight. After covariate adjustment, the 
treatment effect on total cholesterol became limited to the higher 
level of fish consumption (Table 11). The significant treatment 
effect on HDL-cholesterol disappeared completely after adjusting for 
covariates (total and saturated fat). The effect of treatment on 
LDL-cholesterol remained even after adjusting for covariates (total 
and saturated fat). 
Detailed results of the acceptability questionnaire are pre­
sented in Appendix H. In general the results indicated that there was 
little difference between the acceptability scores for smell, taste, 
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Table 11 
Adjusted Means by Treatment 
Dietary Treatment 
Variables 
Parameters Control Moderate High Adjusted For 
Triglycerides^ 
(mg/dl) 
254.3 227.62 229.82 none 
Total-C1 
(mg/dl) 
249.2 24b .4 23b.62 fat, satu­
rated fat, 
weight 
HDL-C 
(mg/dl) 
40.0 39.8 41 .1 fat, satu­
rated fat 
LDL-C1 
(mg/dl) 
159.4 157.2 149.52 fat, satu­
rated fat 
PT1 22.8 23.6 24.22 none 
^Statistically significant treatment effect £<..0b 
2 Significantly different from control mean, individual £ values 
set at <. 0.02b to maintain an overall alpha of u.Ob 
appearance, and portion size. However, significantly different 
responses were observed between the two feeding frequencies of salmon 
consumption. Sixty-seven percent of the subjects consuming salmon 
four times per week considered this level of consumption as too much, 
whereas those consuming the fish two times per week considered this 
level of consumption as just right (72%). The results also indicated 
that most subjects (67%) would prefer to consume salmon two times per 
week but consumption of salmon three times per week also appeared to 
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be well accepted (46%). The percent of subjects who indicated that 
they enjoyed consuming the salmon was similar between two feeding 
frequencies (78%) for two times versus 72% for four times. However, 
the participants indicated that the major problems associated with 
adherence to the salmon regime were those that involved incorporating 
the fish into the menu and family routine. The majority of partici­
pants expressed willingness to continue consuming as much fish as 
they did during the study. 
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CHAPTER V 
DISCUSSION 
The results of the present study suDport the well known 
hypotriglyceridemic effect of n-3 PUFAs. A reduction in serum TG was 
observed at both levels of salmon feeding. Studies conducted in 
patients with hyperlipidemia who were fed diets containing marine 
fish oils have consistently shown marked decreases in plasma TGs. 
Phillipson et al. (198b) fed 20 g of n-3 PUFAs as salmon oil to 20 
type lib hypertriglyceridemic patients and observed a 64% decrease in 
plasma TG. Other studies conducted in hyperlipidemic subjects have 
also reported reductions in plasma TG ranging from 25% to 70% (Harris, 
et al., 1984; Saynor et al., 1984; Simons et al., 1985; Sullivan, 
et al1986). 
All these trials conducted in hyperlipidemic subjects have used 
fish oils or combinations of fish oils and fatty fish in large 
quantities; levels far in excess of that which would be expected to 
be included in the diet: The amounts of n-3 PUFAs fed in the present 
study were only 3-6% of the amount used by Phillipson et al. (1985), 
and these small amounts resulted in a 10% decrease in plasma TG. 
The only other study that used amounts of n-3 PUFAs similar to 
the dose in the present study was conducted in normolipidemic indi­
viduals (Fehily et al., 1983). These researchers reported a 6% 
decrease in plasma TG which was approximately half of that which was 
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seen in the present study. Leaf and Weber (1988) have hypothesized 
that if similar amounts of n-3 PUFAs as fed to normals were consumed 
by hyperlipidemic individuals, the results in hyperlipidemic indi­
viduals would be much more dramatic. Comparison of the data collected 
in this study with data of Fehily et al. (1983) tends to support the 
hypothesis of Leaf and Weber (1988). 
Whether a 10% decrease in plasma TG of hyperlipidemic men 
reduces their risk for CHD remains to be determined. Ahrens (1985) 
and Austin (1989) have assessed hypertriglyceridemia as an independent 
risk factor for CHD. Univariate analytic techniques suggest that 
high TG levels are associated with higher risk for CHD. However, 
when all other known risk factors are entered into multivariate 
analysis, plasma TG levels are only slightly indicative of increased 
risk for CHD. Hulley, Rosenman, Bawol, and Brand (1980) reviewed 27 
epidemiologic-based studies and concluded that hypertriglyceridemia 
was not a reliable risk factor for CHD. 
Multiple etiological factors make patients with hypertri­
glyceridemia an extremely heterogeneous group (Ahrens, 1985). Large 
intraindividual and interindividual variations lead to lower precision 
in TG determination as compared to other lipid measurements (Ahrens, 
1985; Austin, 1989). Factors such as those listed above may partly 
explain why TGs do not generally emerge as an independent risk factor 
in multivariate statistical models. However, the role of TGs in the 
development of atherosclerosis can not be excluded. Very low density 
lipoprotein of hypertriglyceridemic subjects is shown to be involved 
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in the atherogenesis process; they are implicated in the conversion of 
monocytes to foam cells which are toxic to endothelial cells 
(Gianturco & Bradley, 1988). Therefore, Austin (1989) has suggested 
that it is premature to dismiss TG as a risk factor for CHD. Ahrens 
(1985) reported that despite the heterogeneity seen in hypertri-
glyceridemic individuals, they are homogeneous in at least one 
respect; they all show marked decreases in plasma TG levels when fed 
diets containing fish oils.-
To summarize, a recommendation to increase consumption of fish 
rich in n-3 PUFAs in the management of hypertriglyceridemia is con­
sistent with the TG lowering effect of n-3 PUFAs. 
The impact of feeding a diet rich in n-3 PUFAs on total 
cholesterol was limited, after covariate adjustment, to the higher 
level of fish consumption. Other studies conducted in hyperlipidemics 
have always used large amounts of n-3 PUFAs and have generally 
reported hypocholesterolemic effects (Harris & Connor, 1980; 
Phi 11i pson et al., 1981; Phi 11i pson et al., 19b5; Simons et al., 1985; 
Sullivan et al., 1986). When n-3 PUFAs were fed in doses of up to 
20 g per day, an 8 to 48% reduction in total cholesterol has been 
reported by these investigators. Since no data are available on 
hyperlipidemics consuming fatty fish in realistic amounts, it is 
difficult to compare present results with other feeding trials. The 
results of the present study suggest that ingestion of as little as 
1.3 g of n-3 PUFAs per day from a food source was sufficient to 
significantly reduce the elevated serum cholesterol levels. However, 
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at lower levels of salmon feeding (approximately 0.65 g of n-3 PUFAs 
per day) confounders such as total and saturated fat intake and body 
weight were partly responsible for the observed reduction in levels 
of total cholesterol. 
A positive relationship between body weight and serum choles­
terol has been shown by many investigators Kannel, Gordon, & Castelli, 
1979; Kromhout et al., 1983; Montoye, Epstein, & Kjelsberg, 1966; 
Nichols, Ravenscroft, Lamphiear, & Ostrander, 1976). In the present 
study average body weight was lower for the groups consuming moderate 
and high levels of salmon as compared to individuals consuming their 
customary diet. Analysis of covariate which included weight suggested 
that in the group where' individuals received two servings of salmon 
per day, the reduction in cholesterol levels could in part be attrib­
uted to reduced body weight. 
Those studies which have fed comparable amounts of fatty fish, 
i.e., .65-1.3 g per day, to healthy subjects have not shown a hypo-
cholesterolemic effect (Fehily et al., 1983; Spiller et al., 1987). 
It has been hypothesized by other researchers who fed similar amounts 
of n-3 PUFAs that one should expect more dramatic lipid lowering 
effect in hyperlipi demies than in normolipi demies (Leaf & Weber, 
1988). 
The average reduction in total cholesterol after covariate 
adjustment was 10.6 mg which represents a 4% decrease in the choles­
terol level from the level of the control group (249 mg per dl). 
According to the results from the Lipid Research Clinics (LRC) 
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primary prevention trials conducted in asymptomatic hyperlipidemic 
men, a 4% reduction in cholesterol may represent an 8% reduction in 
the CHD events (Lipid Research Clinics Program, 1984). The National 
Cholesterol Education Program categorized individuals with blood 
cholesterol levels of 240 mg per dl as high risk and those with 
blood cholesterol of 200-239 mg per dl are considered borderline risk 
(Ernst, Cleeman, Mullis, Sooter-Bochenek, & Van Horn, 1988). Results 
of the present study indicate that consumption of salmon reduced the 
average cholesterol levels by 10 mg which resulted in the change of 
status of subjects from high to borderline risk for CHD. 
In conclusion, two servings of salmon (8 oz each) per week 
(0.65 n-3 PUFAs per day) were not sufficient to significantly lower 
the elevated cholesterol levels, whereas four servings of salmon 
(8 oz each) per week (1.3 g n-3 PUFAs per day) did have a significant 
hypocholesterolemic effect in hyperlipidemic individuals. 
Beneficial effects of feeding salmon have also been seen with 
LDL-cholesterol in the present study. The difference, a decrease in 
LDL-cholesterol, was observed between the higher level of feeding 
salmon and the customary diet. Consistent results have been reported 
when type lib hyperlipidemics have been fed n-3 PUFAs. Some investi­
gators have shown a decrease in LDL-cholesterol levels as a result of 
n-3 PUFA feeding. A mechanism has been hypothesized by which n-3 
PUFAs might affect LDL-cholesterol. Saynor et al. (1984) suggest that 
reduction in LDL-cholesterol may result from the reduced synthesis of 
VLDL. Although VLDL concentration was not measured in the present 
study, the reduced LDL levels which were a result of salmon feeding 
50 
tend to support the latter hypothesis. Analysis of covariance indi­
cated that the beneficial effect of n-3 PUFAs on LDL-cholesterol con­
tinued to persist even after adjusting for changes in dietary vari­
ables such as total and saturated fat. 
A significant increase in HDL-cholesterol was observed in 
unadjusted data as a result of salmon feeding. However, analysis of 
covariance indicated that the effect of n-3 PUFAs on HDL-cholesterol 
after adjusting for saturated and total fat in the diet disappeared. 
Studies with hyperlipidemic men have generally shown increased HDL-
cholesterol levels (Saynor, 1984; Saynor et al ., 1984; Simons et al, 
1985). These researchers have reported increases in HDL-cholesterol 
in subjects who consumed at least 10 g of MaxEPA oil for a minimum of 
eight weeks. A higher dosage of fish oil (20 ml MaxEPA oil) has been 
demonstrated to shorten the response time (4 weeks) in the HDL frac­
tion. Of those studies which fed realistic amounts of fatty fish to 
healthy individuals, only the study conducted by Spiller et al. (1987) 
has shown increased HDL-cholesterol at levels as low as 100 g fish 
per day (1 g n-3 PUFAs). However, the studies that have shown an 
increase in HDL levels have not included an analysis of the effect in 
the presence of potential confounders as was done in the present 
study. Probably larger doses of n-3 PUFAs and/or their long time 
consumption are required before beneficial effects on HDL-cholesterol 
levels are observed in hyperlipidemic individuals. 
An increase in prothrombin time was noted only at the higher 
level of salmon feeding which provided 1.3 g n-3 PUFAs per day. 
Prothrombin time is a test of the extrinsic pathway involved in blood 
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clotting and is the final common pathway of clotting. The final 
pathway of clotting involves the activity of thrombin. Thrombin is 
actively controlled via two mechanisms; one involves the existence of 
a thrombin antagonist antithrombin III, the other involves the 
inactive thrombin zymogen prothrombin. Since plasma levels of anti­
thrombin III have been demonstrated to increase in subjects fed 
supplements of 10 g of fish oil (Mortensen, Schmidt, Nielsen, & 
Dyerberg, 1983), there is the possibility that fibrin clot formation 
may be altered by n-3 PUFA feeding. A study where 2 g EPA supple­
ments per day were fed to human subjects, however, failed to demon­
strate an increase in the prothrombin time (Nagakawa, Orimo, Harasawa, 
Morita, Kashirok, & Murota, 1983). The results of the present study 
do not support the findings of Nagakawa et al. (1983) . There have 
not yet been sufficient studies conducted to determine, with confi­
dence, the degree to which n-3 PUFAs alter prothrombin time. 
Many scientists believe that the beneficial antithrombotic 
effects of fish oils on CHD are best explained by their effects on 
platelets and endothelial cells (National Dairy Council, 1988). 
Measurement of parameters such as platelet aggregation, amounts of EPA 
and DHA in the endothelial cells, and measurement of key compound in 
prostaglandin synthesis would have added to this body of knowledge, 
but due to financial constraints, these tests were not performed in 
the present study. 
There are several features regarding the design and analysis 
which strengthen the interpretation of the results obtained in the 
52 
present study. First, in the Latin square design employed, subjects 
served as their own controls thereby reducing the error variance. 
Second, the analysis design permitted the treatment effect be adjusted 
for any residual effects of the previous treatment phase. Third, 
removal of the influence of other dietary factors did not in most part 
effect the lipid results. It should be noted that most other studies 
in the literature have not accounted for other confounding dietary and 
environmental factors. It is possible that if other factors had been 
accounted for in these studies the effect of n-3 PUFAs on blood 
lipids might have been somewhat diminished. 
One limitation of the present study appears to be in the esti­
mation of dietary intake. The total caloric estimate seems to be 
very low (approximately 1400 Kcal) as compared to values generally 
reported for men of similar age range (approximately 2500 Kcal). 
Underreporting of actual intake was suspected, but personal communi­
cation with the dietitian at the Cardiac Rehabilitation Center did 
not support this suspicion. If one accepts that the actual descrip­
tion of foods accurately reflects intake, then the error could have 
been introduced at the level of the calculation of nutrient intake 
and may be inherent to the food composition data base. Several recent 
studies have demonstrated that different nutrient values are obtained 
depending upon the nutrient data base system utilized in the calcu­
lation (Medlin & Skinner, 1988). Nutritionist II was used to analyze 
food intakes in the present study which has a data base of 900 foods. 
Medlin and Skinner (1988) have addressed problems which are inherent 
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in smaller data bases; the availability of a limited number of foods 
from which to select may lead to an underestimation of actual 
nutrient intake. In the present study even though actual nutrient 
intake may have been underestimated, it was a systematic bias across 
all nutrients, subjects and treatment periods. Thus, it should have 
had little impact on influencing the results from this study. In 
addition, the investigative staff had great confidence that the 
subjects consumed the fish provided, and communication with the sub­
jects, spouses and staff of the Cardiac Rehabilitation Center 
supported this assertion. 
Encouraging results, however subjective in nature, were 
obtained from the assessment of the acceptability of the fish by the 
subjects. Results indicated that the participants accepted salmon 
for its organoleptic characteristics (smell, taste, appearance, and 
portion size) equally across the two feeding frequencies. As antici­
pated, most participants indicated that consuming the same fish four 
times per week was somewhat burdensome and that consuming fish three 
times per week was more acceptable. 
Comparing these results with any other data is not possible, 
because no one to date has assessed the acceptability of fish in 
amounts beneficial to reduce the risk for CHD either in healthy or 
hyperlipidemic individuals. The problems encountered by participants 
in adhering to the fish diet were those that involved incorporating 
the fish into the menu and family routine. It is anticipated that 
these difficulties would be overcome if the salmon was integrated 
into the entire family's eating pattern. 
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Despite all the inconveniences the participants responded 
affirmatively when asked if they would consume similar amounts of fish 
in the future. However, such affirmative responses need to be inter­
preted with care because of the way the question was worded. The 
current question asked was, "Would you consume as much fish again?" 
and could have been interpreted to mean that someone else was pro­
viding the fish. If the question had been "Would you consume as much 
fish again at your own expense?", the response might have been 
different. 
To summarize, the consumption of fish at levels which provide 
1.3 g of n-3 PUFAs does benefit hyperlipidemic individuals by decreas­
ing lipid levels. However, any claim regarding antithrombotic 
properties of n-3 PUFAs cannot be made based on the present data. It 
is encouraging, though, that the observed effect on prothrombin time 
is in a direction similar to that which has been suggested in the 
literature. The acceptability data provides a bridge between the 
heart-healthy claims and the acceptance of fish by people and indi­
cates that people may be willing to consume fish more frequently if 
they perceive that fish can reduce their risk for CHD. 
Based on the results of the present study, it seems prudent to 
recommend that individuals consume more fish rich in n-3 PUFAs, and 
substituting fish for foods rich in SFAs may also be an effective 
strategy for reducing the SFA content of the diet. Fish oil capsules 
are not recommended as a therapeutic measure because their benefits 
and safety have not been proven. The more prudent procedure, there­
fore, appears to be for a person to include more fish in the diet. 
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CHAPTER VI 
RECOMMENDATIONS FOR FUTURE RESEARCH 
The potential role of dietary augmentation with n-3 PUFAs is 
promising but has yet to be resolved. Review of the literature and 
results of the present study have presented many potentials for n-3 
PUFAs. Experimental trials in human subjects have generally involved 
large doses of n-3 PUFAs either in the form of fish oil or combina­
tions of fish oils and fatty fish. Few studies have examined the 
effects of fatty fish consumption in realistic amounts, and such 
studies are generally conducted with healthy individuals. The Dresent 
study was the first to study the effects of n-3 PUFAs when consumed 
in moderate amounts by hyperlipidemic individuals, and the results 
have been encouraging. The study was, however, short term, and the 
sample size of the study was small. Long-term intervention studies 
of moderate amounts of n-3 PUFA, using a larger sample, are recom­
mended for stronger evidence of the beneficial effects of n-3 PUFAs. 
Intensive long-term research efforts are also needed to determine the 
minimum dosage of n-3 PUFAs for optimum benefits before dietary recom­
mendations can be made to the general public. 
Subjects in the present study were chosen because they liked 
fish. One can, therefore, assume that these subjects were receiving 
some amount of n-3 PUFAs in their diet before the study. It would be 
worthwhile to study the effects of adding realistic amounts of fish 
to a totally fish-free diet. 
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The results of the present study also indicated that the 
covariates, such as total and saturated fat, had an effect on lipid 
levels. The effectiveness of n-3 PUFAs in moderate amounts, at 
different levels of total and saturated fat consumption in humans, 
needs further assessment. Studies that monitor effects of various 
dietary levels of n-6 PUFAs on the response to n-3 PUFAs feedings in 
humans are also required. Research in this area will aid in under­
standing whether the effect of n-3 PUFAs is more pronounced when 
diet is limited in other fats. During the course of the present 
study, it was often asked if salmon was the only fish that was good 
to reduce the risk of CHD. Since only salmon was used as a source of 
n-3 PUFAs in the present study, it is recommended for future studies 
that various fish species be used and comparisons be made of their 
effects in the same subjects because people generally consume a 
variety of foods. Success in recommending increased fish consump­
tion can be achieved only if people would consume a variety of 
different fish to receive the benefits of n-3 PUFAs. 
Evidence indicates that n-3 PUFAs may decrease the risk of CHD 
because of the antiaggregatory effect which results from competitive 
inhibition of formation of proaggregatory metabolites of AA (Siess 
et al., 19B0). To date parameters such as bleeding time and platelet 
aggregation have generally been used to study the antiaggregatory 
effects of n-3 PUFAs. Assessment of additional parameters such as 
concentration of n-3 PUFAs in platelets and measurement of urinary 
metabolites of antiaggregatory prostanoids need to be made when 
varying amounts of n-3 PUFAs and n-6 PUFAs are fed. This will allow 
a researcher to determine an optimal ratio of n-3 and n-6 PUFAs in 
the diet, and the levels of n-3 PUFAs required to favorably alter 
prostaglandin synthesis. 
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Acceptability Questionnaire 
Diet 
Please answer all the following questions which will help us learn 
how the fish diet over the past four weeks is fitting into your 
routine. 
1. Rate the following characteristics of the fish diet you consumed 
for the last four weeks. 
Good Average Poor Other 
Smel 1 
Taste 
Appearance 
Portion Size ' 
2. Rate the frequency of consumption. 
Too much 
Just right 
Too little 
3. How many times per week would you like to consume fish? 
Once 
Twice 
Three times 
Other 
4. Did you enjoy consuming salmon for the past four weeks? 
Yes 
No 
Other 
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5. If your answer to question no. 4 is no, please check the other 
kind(s) of fish you would like to consume. 
Mackerel 
Herring 
Trout 
Flounder 
Tuna 
Other 
6. Check all the problems you experienced in adhering to the fish 
diet for the last four weeks. 
Portion size 
Smell of fish 
Taste of fish 
Physical discomfort 
Fitting in the menu 
Fitting in the family routine 
Inflexibility to go out to eat 
Other 
7. Would you consume as much fish as you did for the last four weeks 
again? 
Yes 
No 
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Plasma Lipid Values for Eligible Participants 
Age 
Total Cholesterol 
75th Percentile 
and Above (mg/dl) Age 
Total Triglycerides 
75th Percentile 
and Above (mg/dl) 
40-49 231 45-49 165 
50 230 50-54 178 
55-59 167 
60-65 150 
Note. Taken from The Lipid Research Clinics Population Studies Data-
book (Vol. 2). (NIH Publication No. 80-1527) 
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General Information About the Study 
Fish and Heart Disease 
Department of Food, Nutrition and Food Service Mangement 
School of Home Economics 
The University of North Carolina at Greensboro 
There is a growing evidence that consumption of dietary omega-3 
polyunsaturated fatty acids (n-3 PUFAs), abundant in marin organisma, 
may reduce the development of cardiovascular disease. Omega-3 PUFAs 
have two important effects in the body which may impact on the 
development of heart disease. These fatty acids are known to lower 
the elevated serum lipids and also alter platelet function (bleeding 
factors). The hypolipidemic effects of n-3 PUFAs appear to be con­
sistent only when high levels of either fatty fish or a fish oil 
extract have been consumed by people. Similar observations have been 
made when dietary habits of the Eskimos were studied. 
At lower intakes of n-3 PUFAs, the effects are less discernible 
and to date there have been fewer studies which have attempted to 
determine the impact of consumption of low levels of n-3 PUFAs. The 
studies that have studied the effects of fish consumption in moderate 
amounts have suggested that the mean capital intake of fish is 
currently about 3 ozs per week and any increase in fatty fish con­
sumption may prove beneficial in reducing the risk of cardiovascular 
disease, particularly in those individuals with elevated serum lipids. 
It is also worth mentioning here that Eskimos are known to have 
prolonged bleeding time which is associated with their excess con­
sumption of fatty fish. However, the amount of fish consumed by the 
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United States population at large, and in the proposed study, does 
not pose a danger of bleeding disorder, and consumption in moderate 
amounts may not be harmful. 
The present study is, therefore, designed to study the lipid 
lowering effects of fish consumption. An informed consent is sought 
from the people who would like to volunteer for the participation in 
the proposed study. 
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Consent Form 
Fish and Heart Disease 
Department of Food, Nutrition and Food Service Management 
School of Home Economics 
The University of North Carolina at Greensboro 
General 
I understand that the purpose of this research study is to 
evaluate the effects of fish consumption on blood lipid (fats) 
levels—total cholesterol, HDL-cholesterol , total triglycerides and 
platelet function. Participation in the study requires me to follow 
three different dietary regimes over a period of twelve (12) weeks. 
I understand that I will be randomly assigned to each dietary regime 
j 
for a four-week period (random assignment is similar to a flip of a 
coin where everyone has an equal chance of being selected). 
Dietary Regimens 
Following are the three dietary regimens: 
1. I understand that I will consume eight ounces (ozs) of fish 
(salmon) four times a week for four weeks. The fish will 
provide a certain amount of polyunsaturated fatty acids 
(PUFAs) that I need. The remainder of the PUFAs will be 
provided in the form of safflower oil which will also be 
provided by the research investigator. 
2. During the other four weeks, I will consume eight ounces 
of fish (salmon) two times a week for four weeks. 
Safflower oil will be provided as needed. 
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3. During another period of four weeks, I will consume only 
safflower oil to get all the PUFAs I need. 
I understand that fish will be provided to me in cooked form, and 
safflower oil can be used for cooking purposes. 
I understand that I will be required to follow certain dietary 
guidelines during the entire study. A draft of the dietary guidelines 
is as follows: 
1. Do not eat an egg on the fish day. 
2. Restrict visible fat (butter, cream, margarine, salad 
dressing) to three teaspoons a day. Do not prepare foods 
with added fat from animal sources. Restrict the use of 
butter and animal fats. 
3. Avoid the use of other meats on the fish day. 
4. Try to avoid consumption of any vegetable oil during fish 
meal and restrict it on fish day. 
I understand that I will be asked to keep a four-day diet 
record at the beginning of the study and at the end of each four-week 
period. This is similar to the seven-day diet record which I provide 
to the cardiac rehabilitation program. 
I will also be required to fill out a simple questionnaire at 
three different times during the entire study period of twelve (12) 
weeks. The questionnaire will only assess my acceptability of the 
diet consumed during the previous four weeks. 
I understand that all the aforementioned procedures will be 
performed at the cardiac rehabilitation program after my exercise. 
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Explanation of Risks 
I understand that 30 cc of blood will be drawn at the beginning 
of the study and at the end of each study period. 
I understand that I may experience some discomfort such as 
bruising or lightheadedness associated with blood drawing procedures. 
I realize that all possible precautions will be taken in order to 
reduce the risks associated with drawing blood. 
Explanation of Benefits 
The benefits I may gain from participating in this research 
study include: an assessment of blood lipid profile and an evaluation 
of my dietary adequacy. In addition, I will be able to consume cooked 
fish free of cost which is recommended for heart disease patients. 
I understand that all data collected will be coded to main­
tain confidentiality. I understand that I can withdraw from the 
study at any time. 
Dr. Karen Graves or another research staff member will be 
available to answer any questions about the study. They may be 
reached at the University of North Carolina at Greensboro Nutrition 
Department on weekdays at (919) 334-5313. Dr. Henry Miller will 
also be available to answer questions about the research. Questions 
regarding the research subjects' rights will be answered by the 
Chairman, Clinical Research Practices Committee through the Office 
of Research Development (919-748-4542). 
Signature of Subject 
Date 
Signature of Witness 
Date 
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Recipes 
Lemon Poached Salmon 
4 6 oz fresh or frozen salmon steaks 
1/3 cup lemon juice 
1/4 cup chopped celery 
1/8 teaspoon freshly ground pepper 
tartar sauce (see recipe below) 
4 cups water 
1 small onion, sliced 
1/2 teaspoon salt 
lemon wedges 
Thaw salmon if frozen. In large skillet combine water, lemon juice, 
onion, celery, salt, and pepper. Bring to boil; simmer five minutes. 
Add salmon; simmer, covered, 7 to 10 minutes or until fish flakes 
easily with a fork. Remove salmon from liquid with spatula. Chill 
or serve hot. Serve salmon with lemon wedges. If desired, top 
salmon with tartar sauce and garnish with fresh dill weed. Makes 
4 servings. 
Tartar Sauce 
1/2 cup whipped mayonnaise-type 
salad substitute (no more than 
20 calories per tablespoon) 
1 teaspoon finely chopped onion 
1 teaspoon finely chopped pimento 
1/4 cup finely shredded carrot 
1 tablespoon finely chopped 
pickle 
1 teaspoon snipped parsley 
1 teaspoon lemon juice 
Combine salad dressing, carrot, dill pickle, onion, parsley, pimento, 
and lemon juice. Cover and chill thoroughly. Serve with fish. Makes 
3/4 cup sauce. One serving (2 tablespoons) 
Lemon-Parsley Salmon 
1 quart water 
2 teaspoons chicken-flavored 
bullion granules 
1/2 teaspoon whole peppercorns 
1/4 teaspoon garlic powder 
1 one pound salmon fillet 
fresh tarragon leaves (optional) 
1 cup fresh parsley sprigs 
1 tablespoon fresh tarragon 
leaves or 1 teaspoon dried 
whole tarragon 
4 1/4 in. thick lemon slices 
lemon wedges (optional) 
Combine first 7 ingredients in a large skillet. Bring mixture to a 
boil; reduce heat, and simmer, uncovered, 10 minutes. Rinse salmon 
under cold, running water; pat dry. Add salmon, if necessary. Return 
to a simmer; cover and cook over low heat 10 to 12 minutes or until 
salmon flakes easily when tested with a fork. Remove salmon from 
skillet, using a slotted spoon; discard liquid. Cut fillet into 4 
equal portions; garnish with lemon wedges and tarragon, if desired. 
Yield: 4 servings. 
79 
Baked Salmon Steaks with Caper Sauce 
2 tablespoons plain low-fat yogurt 
2 tablespoons reduced calorie 
mayonnaise 
1 teaspoon capers, drained 
1/2 teaspoon low-sodium lemon-
pepper seasoning 
2 4-oz. salmon steaks 
fresh dill sprigs (optional) 
1 small onion, thinly sliced 
1 tablespoon dry white wine 
1 tablespoon chopped fresh dill 
or 1 teaspoon dried whole 
dill weed 
lemon slices (optional) 
vegetable cooking spray 
Combine first 5 ingredients, mixing well. Cover and chill. Rinse 
salmon under cold, running water; pat dry. Place in a 1-quart baking 
dish coated with cooking spray. Arrange onion slices over salmon. n 
Pour wine over salmon and sprinkle with dill. Cover and bake at 350 
for 15-20 minutes or until salmon flakes easily when tested with a 
fork. Discard onion and dill and transfer salmon to individual 
serving plates. Spoon 2 tablespoons caper mixture over each salmon 
steak and garnish with lemon slices and fresh dill, if desired. 
Yield: 2 servings 
Broiled Cilantro Salmon1 
1/4 cup chopped onion 
1/4 cup chopped tomato 
1/8 teaspoon white pepper 
2 tablespoons lime juice 
1 tablespoon low sodium soy 
sauce 
vegetable cooking spray 
1/4 cup chopped red bell pepper 
3 tablespoons chopped fresh 
cilantro 
1 tablespoon vegetable oil 
1 clove garlic, crushed 
4 4-oz. salmon steaks 
fresh cilantro sprigs (optional) 
Position knife blade in food processor bowl; add first 9 ingredients; 
top with cover and process until mixture is smooth. Rinse salmon 
under cold, running water, pat dry. Place salmon in a 12 x 8 x 2 inch 
baking dish. Pour 1/4 cup cilantro mixture over salmon, turning to 
coat well. Set aside remaining cilantro mixture. Cover and chill at 
least 4 hours, turning occasionally. Remove salmon from marinade, 
discarding marinade. Place on rack of a broiler pan coated with 
cooking spray. Broil 4-5 inches from heat for 5 minutes or until fish 
flakes easily when tested with a fork. Transfer to a serving platter; 
serve with reserved cilantro mixture. Garnish with cilantro sprigs, 
if desired. Yield: 4 servings 
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Poached Fish with Dill Sauce 
1 3-1b. fresh or frozen dressed fish 
1/4 teaspoon dried tarragon, crushed 
2 tablespoons butter or margarine 
4 teaspoons all-purpose flour 
1/2 teaspoon sugar 
1 beaten egg yolk 
2 cups water 
3 lemon slices 
1 bay leaf 
2 teaspoons lemon juice 
1/2 teaspoon dried dill 
weed 
Thaw fish, if frozen. Place on large piece of cheesecloth; fold cloth 
over fish. Place on rack in poaching pan. Add water, lemon slices, 
bay leaf, tarragon, and 1 teaspoon salt. Cover and simmer 25-30 
minutes or until fish flakes easily when tested with fork. Remove 
from pan; keep warm. Strain and reserve 1 cup cooking liquid. For 
sauce, in saucepan melt butter; stir in flour. Add reserved liquid, 
lemon juice, sugar, dill week and dash of salt. Cook and stir until 
thickened and bubbly. Gradually stir 1/2 cup of hot mixture into egg 
yolk; return to hot mixture. Cook and stir 1-2 minutes more. Pull 
cloth away from fish; remove and discard skin. Transfer fish to 
platter using 2 spatulas. Top with some sauce. Pass remaining. 
Makes 6 servings 
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Analysis of Variance Results: Analysis to Estimate Residual Effect 
Triglyceride 
Source 
lb 
Period (sq) 
Direct Effect (adj) 
Residual Effects (adj) 
Error 
Total Cholesterol 
ID 
Period (sq) 
Direct Effect (adj) 
Residual Effects (adj) 
Error 
HDL-C 
ID 
Period (sq) 
Direct Effect (adj) 
Residual Effects (adj) 
Error 
LDL-C 
ID 
Period (sq) 
Direct Effect (adj) 
Residual Effects (adj) 
Error 
df 
17 
4 
2 
2 
28 
17 
4 
2 
2 
28 
17 
4 
2 
2 
23 
17 
4 
2 
2 
28 
SS 
937403 
3481 
6540 
2467 
5946 
47173 
276 
1835 
134 
1252 
3543 
64 
46 
9 
147 
26964 
276 
1347 
340 
1442 
15.40 
5.81 
20.52 
1 .51 
4.37 
9 
1308 
330 
.0001 
.0077 
.0001 
.2387 
.0224 
.4046 
.0001 
.0515 
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Prothrombin Time 
Source df SS F P 
ID 17 463 
Period (stl) 4 34 
Direct Effect (adj) 2 18 6.64 .0044 
Residual Effects (adj) 2 1 .36 .6975 
Error 28 37 
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Analysis of Variance Results: Analysis of 
Blocking on Individual and Period 
Total Cholesterol 
Source df SS F P 
ID 17 3543 
Period 2 63 
Treatment 2 37 3.7 .0349 
Error 32 159 
HDL-C 
ID 17 3543 
Period 2 63 
Treatment 2 37 3.7 .0349 
Error ' 32 159 
LDL-C 
ID 17 26965 
Period 2 214 
Treatment 2 1129 9.8 .0005 
Error 32 1846 
Prothrombin Time 
ID 17 463 
Period 2 32 
Treatment 2 18 12.8 .0001 
Error 32 40 
APPENDIX G 
ANALYSIS OF COVARIANCE: ANALYSIS TO 
ADJUST FOR POTENTIAL CONFOUNDERS 
87 
Analysis of Covariance: Analysis to Adjust for Potential Confounders 
Total Cholesterol 
Source df 
ID 17 
Period 2 
Treatment 2 
Fat 1 
Saturated Fat 1 
Weight 1 
Error 26 
HDL-C 
ID 17 
Period 2 
Treatment 2 
Fat1 1 
Saturated Fat 1 
Error 27 
LDL-C 
ID 17 
Period 2 
Treatment 2 
Fat 1 
Saturated Fat 1 
Error 27 
SS F P 
25626 
145 
632 10.08 .0006 
441 16.07 .0009 
337 10.74 .0030 
119 3.79 .0623 
816 
2953 
61 
16 1.70 .2016 
4 .90 .3503 
14 2.98 .0960 
129 
25005 
180 
836 8.93 .0011 
491 10.58 .0031 
301 6.48 .0169 
1254 
^Type 1 SS showed that fat made a significant difference. 
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Results of Acceptability Questionnaire 
Question 1: Overall Characteristics (average scored 
2 Times Per Week 4 Times Per Week 
Smell 2.27 2.17 
Taste 2.56 2.50 
Appearance 2.61 2.83 
Portion Size 2.61 2.61 
Average 2.51 2.53 
Hhe higher the score the more positive the response. 
Question 2: Frequency of Consumption (% of participants)^ 
2 Times Per Week 4 Times Per Week 
Too much 17 67 
Just right 72 33 
Too little 11 0 
^responses were significantly different between the two frequency 
categories. 
Question 3: How many times per week (% of participants) 
2 Times Per Week 4 Times Per Week 
Once 6 11 
Twice 67 39 
Three times 17 44 
Other 11 6 
Question 4: Enjoyment (% responding positively) 
2 Times Per Week 4 Times Per Week 
78 72 
Question 5: (not analyzed (subject did not follow instructions) 
Question 6: Problems with adherence (% responding affirmatively) 
2 times per week 4 Times Per Week 
Portion size 5 5 
Smel 1 11 33 
Taste 33 
90 
Question 6: Problems with adherence (% responding affirmatively) 
2 Times Per Week 4 Times Per Week 
Portion size 5 5 
Smell 11 33 
Taste 33 11 
Physical discomfort 5 5 
Fitting in routine 33 44 
Fitting into family routine 50 44 
Inflexibility 22 17 
Question 7: Would you consume as much again (% responding 
affirmatively) 
2 Times Per Week 4 Times Per Week 
83 72 
